Product Name: Sitafloxacin Hydrate CAS NO:163253-35-8
7-[(7S)-7-Amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-4-oxoquinoline-3-carboxylic acid hydrate (2:3);
Chemical & Physical Properties:
Appearance : off-white to light yellow powder
Boiling Point:629.2℃ at 760mmHg
Sitafloxacin is a quinolone broad-spectrum antibacterial drug, which was successfully developed by Japan Daiichi Pharmaceutical Sankyo Co., Ltd. It has good pharmacokinetic properties due to its molecular structure containing a cis-fluorocyclopropylamine group. It can reduce adverse reactions, and its in vitro antibacterial activity is significantly enhanced compared with most similar drugs. Oral tablets and fine granules were first launched in Japan in June 2008 for the treatment of severe and refractory infectious diseases. The injection form is undergoing phase III clinical trials in Japan by Japan Daiichi Pharmaceutical Company for the treatment of bacterial infections.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.